H. Bill Bosch

Executive Director & Chief Scientific Officer at iCeutica Pharmaceuticals, Inc.

H. Bill Bosch

H. Bill Bosch

Executive Director & Chief Scientific Officer at iCeutica Pharmaceuticals, Inc.

Overview
Career Highlights

Botanix Pharmaceuticals Ltd.
iCeutica Pharmaceuticals, Inc.
NanoSystems LLC

RelSci Relationships

299

Number of Boards

1

Contact Data
Trying to get in touch with H. Bill Bosch? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals H. Bill Bosch likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman at iCeutica Pharmaceuticals, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at iCeutica Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at Kew Capital LLP

Relationship likelihood: Strong

Founding Partner at Druid BioVentures LLC

Relationship likelihood: Strong

Chief Financial Officer at iCeutica Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder & Investment Director at Yuuwa Capital Management Pty Ltd.

Relationship likelihood: Strong

Chairman at Dimerix Ltd.

Relationship likelihood: Strong

Former Managing Director at Credit Suisse AG (London Branch)

Relationship likelihood: Strong

Former Executive Chairman at Cynata Therapeutics Ltd.

Relationship likelihood: Strong

Co-Founder & Managing Partner at Phoenix IP Ventures LLC

Relationship likelihood: Strong

Paths to H. Bill Bosch
Potential Connections via
Relationship Science
You
H. Bill Bosch
Executive Director & Chief Scientific Officer at iCeutica Pharmaceuticals, Inc.
Career History
Executive Director & Chief Scientific Officer
2007 - Current

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

Director-Pharmaceutical Research
Prior

Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland.

Advisor
Current

Ben Franklin Technology Partners (BFTP) provides seed and early-stage capital to companies in the information technology, life sciences and physical sciences sectors. Their Innovation Fund provides up to $100,000 to technology companies for prototype refinement and/or very early commercialization efforts. BFTP's Emerging Fund invests up to $750,000 in technology companies over multiple financing rounds for product or process development and/or commercialization efforts. Their Technology Commercialization Fund invests up to $350,000 in select university and research institution spin-out companies. Companies must be commercial, for-profit businesses located in the Pennsylvania counties of Buck, Chester, Delaware, Montgomery or Philadelphia.BFTP provides early-stage financing to promising life sciences ventures in the biopharmaceuticals, medical devices, diagnostics, biomaterials and healthcare information technology industries. They look for companies with strong management and strong IP and patent protection that are involved in a novel and unique science. Investments range from $100,000 to $500,000 as part of larger funding rounds of $200,000 to $3 million involving other sources such as SBIR, angel, early-stage venture capital and other state funding sources.BFTP also invests in promising physical sciences companies involved in developing advanced materials, sensors, robotics, environmental and consumer goods. They look for companies with strong management and strong IP and patent protection that offer a disruptive and unique technology.

Boards & Committees
Director
Tenure Unconfirmed

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

Transactions
Details Hidden

iCeutica Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

iCeutica Pharmaceuticals, Inc. raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by H. Bill Bosch. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of H. Bill Bosch's profile does not indicate a business or promotional relationship of any kind between RelSci and H. Bill Bosch.